Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2021 | $12.00 | Buy | Maxim Group |
STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference
STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79
STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA
STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025. Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include: In January 2025, the Company announced it had closed a $2.5 million registered direct offering priced at the market under Nasdaq rules.Also in January 2025, we announced that we received positive regulatory guidance from the European Medicines Agency (E
STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference
Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
DEFA14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)